Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ELV US Equity

Elevance Health, Inc.Financials · Hospital & Medical Service Plans · CIK 1156039 · FY ends Dec 31
$398.27
+8.03 (+2.06%)
USD · as of 2026-08-18 · marketstack
1 registered study · 0 active

Studies where ELV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional

Held by 29 tracked-famous managers (HARRIS ASSOCIATES L P, Artisan Partners Limited Partnership, First Eagle Investment Management, LLC, EAGLE CAPITAL MANAGEMENT LLC, BAUPOST GROUP LLC/MA, +24 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: 0 congress / 3 executive

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Asthma Digital StudyNCT04609644Change in asthma-associated expenditures due to emergency department and hospital utilizationRandomized · Open-label · OtherNot applicableCompletedOther: Digital Tools for Asthma Self-ManagementAsthma9012022-11-04actual2023-11-22

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19